KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Depreciation and Depletion (2024 - 2026)

Medtronic's Depreciation and Depletion history spans 3 years, with the latest figure at $308.0 million for Q1 2026.

  • For Q1 2026, Depreciation and Depletion rose 14.93% year-over-year to $308.0 million; the TTM value through Jan 2026 reached $1.2 billion, changed N/A, while the annual FY2025 figure was $1.1 billion, 15.3% up from the prior year.
  • Depreciation and Depletion for Q1 2026 was $308.0 million at Medtronic, up from $282.0 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $322.0 million in Q2 2025 and bottomed at $248.0 million in Q3 2024.
  • The 3-year median for Depreciation and Depletion is $282.0 million (2025), against an average of $282.7 million.
  • The largest YoY upside for Depreciation and Depletion was 16.53% in 2025 against a maximum downside of 7.63% in 2025.
  • A 3-year view of Depreciation and Depletion shows it stood at $262.0 million in 2024, then rose by 7.63% to $282.0 million in 2025, then increased by 9.22% to $308.0 million in 2026.
  • Per Business Quant, the three most recent readings for MDT's Depreciation and Depletion are $308.0 million (Q1 2026), $282.0 million (Q4 2025), and $289.0 million (Q3 2025).